Rimidi Partners with Cellular Scale Company, Yields Promising Results for Heart Failure Management

Monday, March 11, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

ATLANTA, March 11, 2019 /PRNewswire/ -- Rimidi has partnered with BodyTrace, a cellular technology company, to provide

cellular-enabled scales to heart failure patients who are remotely monitored by their clinicians using Rimidi's software platform. The cellular scales provide a frictionless experience for patients; all they have to do is step on the scale and their
weight is automatically transmitted to the Rimidi platform, where their care team can monitor changes in weight that may indicate fluid retention and worsening heart failure.

Rimidi is a cloud-based software solution that enables personalized management of chronic cardiometabolic conditions across populations, including heart failure, type 2 diabetes, and fatty liver disease. Rimidi integrates patient-generated health data from connected devices (such as scales) with patient data in a health system's electronic medical record, giving clinicians a more complete view of each patient's health. The Rimidi platform enables remote patient monitoring and remote patient-provider communication. The platform provides advanced analytics and prompts clinical action when appropriate.

The ability to monitor weight changes in heart failure patients inside of the EHR workflow in conjunction with analytics about other aspects of their heart failure management is key to a scalable heart failure program, according to Lucienne M. Ide, M.D., Ph.D., founder and chief health innovator at Rimidi.

"One of the signs of worsening heart failure is weight gain, indicating fluid retention," said Dr. Ide. "Clinicians can work with Rimidi to set alerts if a patient shows a concerning amount of weight gain over the course of 24 hours or a week. Clinicians can then follow up with patients remotely to see if they're experiencing any other symptoms of worsening heart failure—shortness of breath, coughing, swelling in ankles—before the complications lead to an emergency room visit or hospital admission."

According to Dr. Ide, recording weight at the same time each morning can help clinicians identify early signs of heart failure exacerbation. BodyTrace uses the cellular (GSM) network to transmit the recorded weights directly into Rimidi's system.

"With BodyTrace scales, we really wanted to provide an out-of-the-box solution," said Amit Ghia, VP, Product & Partnerships for BodyTrace.  "There's no complicated syncing, just take the scale out of the box, step on it as often as your clinician directs you to, and let us handle getting that information to your doctor."

The heart failure case management team at Desert Oasis Healthcare (DOHC), part of Heritage Provider Network, has implemented Rimidi's heart failure program using BodyTrace scales to remotely monitor their heart failure patients. This system prevents costly complications and reduces readmissions. DOHC currently monitors over 170 patients using the BodyTrace scales and Rimidi platform.

"The team managing our heart failure patients who use the BodyTrace scale, find it much easier to monitor fluid balance," said Judi Urban, RN, Supervisor of Disease Management at DOHC. "BodyTrace scales used with Rimidi's software, allow us to identify members with fluid overload. This enables quick intervention avoiding worsening of symptoms, and preventing eventual admission to the hospital."

Rimidi partners with a number of connected devices to bring clinicians a more complete view of their patient's health and enable personalized, remote management of cardiometabolic conditions. BodyTrace is continuing to develop cellular-enabled medical devices.

ABOUT RIMIDI

Rimidi is a cloud-based software solution that enables personalized management of chronic cardiometabolic conditions across populations, with specific platforms for diabetes, heart failure, and fatty liver disease. Created by doctors, Rimidi connects patient-generated health data with EHR systems to drive patient-specific clinical insights and actions. The net effect is a better health system with optimized clinical workflows that enable better decisions, better relationships, better outcomes, and ultimately a better healthcare system. For more information, visit rimidi.com.

ABOUT BODYTRACE

BodyTrace is leading the charge to transform digital health. The company develops cellular enabled weight scales that allow a person to use a scale without ever having to worry about pairing or setup. The scale is made from the highest quality materials available and has a proven track record for accuracy and reliability. For more information, visit bodytrace.com.

Cision View original content:http://www.prnewswire.com/news-releases/rimidi-partners-with-cellular-scale-company-yields-promising-results-for-heart-failure-management-300810034.html

SOURCE Rimidi



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store